Institution
Seattle Cancer Care Alliance
Healthcare•Seattle, Washington, United States•
About: Seattle Cancer Care Alliance is a healthcare organization based out in Seattle, Washington, United States. It is known for research contribution in the topics: Transplantation & Cancer. The organization has 728 authors who have published 1268 publications receiving 70663 citations.
Papers published on a yearly basis
Papers
More filters
Medical College of Wisconsin1, Mayo Clinic2, Seattle Cancer Care Alliance3, University of Massachusetts Amherst4, Tufts University5, Imperial College London6, Case Western Reserve University7, Vanderbilt University8, University of Pennsylvania9, University of Texas at San Antonio10, Oregon Health & Science University11, Memorial Sloan Kettering Cancer Center12, University of Florida13, University of Alabama at Birmingham14, University of Massachusetts Medical School15, University of Wisconsin-Madison16, Baylor College of Medicine17, Karolinska Institutet18, Uppsala University19, University of Kansas20, University of South Florida21, University of Virginia22, University of North Carolina at Chapel Hill23, Cornell University24
TL;DR: Post-trans transplantation survival in AL has improved, with a dramatic reduction in early post-transplantation mortality and excellent 5-year survival, and randomized comparison with nontransplantation approaches is again warranted.
Abstract: Purpose Autologous hematopoietic cell transplantation, or autotransplantation, is effective in light-chain amyloidosis (AL), but it is associated with a high risk of early mortality (EM). In a multicenter randomized comparison against oral chemotherapy, autotransplantation was associated with 24% EM. We analyzed trends in outcomes after autologous hematopoietic cell transplantation for AL in North America.
156 citations
University of California, San Diego1, Duke University2, University of Michigan3, Ohio State University4, City of Hope National Medical Center5, Fox Chase Cancer Center6, Yale Cancer Center7, Harvard University8, University of Colorado Boulder9, Case Western Reserve University10, Washington University in St. Louis11, Stanford University12, Johns Hopkins University13, Seattle Cancer Care Alliance14, Northwestern University15, University of Texas MD Anderson Cancer Center16, University of South Florida17, Mayo Clinic18, Memorial Sloan Kettering Cancer Center19, Dana Corporation20, Vanderbilt University21, University of Utah22, University of Alabama23, University of Wisconsin-Madison24, National Comprehensive Cancer Network25
TL;DR: These NCCN Guidelines Insights focus on genes newly associated with CRC risk on multigene panels, the associated evidence, and currently recommended management strategies.
Abstract: The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal provide recommendations for the management of patients with high-risk syndromes associated with an increased risk of colorectal cancer (CRC). The NCCN Panel for Genetic/Familial High-Risk Assessment: Colorectal meets at least annually to assess comments from reviewers within their institutions, examine relevant data, and reevaluate and update their recommendations. These NCCN Guidelines Insights focus on genes newly associated with CRC risk on multigene panels, the associated evidence, and currently recommended management strategies.
155 citations
TL;DR: The common thread regarding LABC/IBC is the consideration of neoadjuvant (also called primary) systemic therapy (NST) as the initial management of choice and the intent of NST in this setting is to improve surgical options and to improve breast cancer survival.
Abstract: Locally advanced breast cancer (LABC) and inflammatory breast cancer (IBC) were both initially commonly defined as breast cancers that were inoperable at presentation and/or as having an extremely poor survival with locoregional treatments alone. The first published descriptions of LABC by Haagensen and Stout in 1943 and of IBC by Bell in 1814 (eventually termed IBC by Lee and Tannebaum in 1924) have essentially held to form over time. Corresponding staging with the sixth edition of the American Joint Commission on Cancer criteria today would encompass the stage IIIA and B breast cancers. However, over time the cohort of LABCs has also tended to include primary tumors greater than 5 cm in size (T3N0 and T3N1). This article and its associated conclusions refer specifically to inoperable LABC and IBC at presentation (Table 1). The common thread regarding LABC/IBC is the consideration of neoadjuvant (also called primary) systemic therapy (NST) as the initial management of choice. The intent of NST in this setting is to improve surgical options (primarily operability) and to improve breast cancer survival.
155 citations
TL;DR: Web-based self-care support and communication coaching added to SxQOL screening reduced symptom distress in a multicenter sample of participants with various diagnoses during and after active cancer treatment.
Abstract: Purpose The purpose of this trial was to evaluate the effect of a Web-based, self-report assessment and educational intervention on symptom distress during cancer therapy. Patients and Methods A total of 752 ambulatory adult participants were randomly assigned to symptom/quality-of-life (SxQOL) screening at four time points (control) versus screening, targeted education, communication coaching, and the opportunity to track/graph SxQOL over time (intervention). A summary of the participant-reported data was delivered to clinicians at each time point in both groups. All participants used the assessment before a new therapeutic regimen, at 3 to 6 weeks and 6 to 8 weeks later, completing the final assessment at the end of therapy. Change in Symptom Distress Scale–15 (SDS-15) score from pretreatment to end of study was compared using analysis of covariance and regression analysis adjusting for selected variables. Results We detected a significant difference between study groups in mean SDS-15 score change from...
153 citations
TL;DR: Increased background parenchymal enhancement on breast MRI is associated with younger patient age and higher abnormal interpretation rate, however, it is not related to significant differences in positive biopsy rate, cancer yield, sensitivity, or specificity of MRI.
Abstract: OBJECTIVE. Breast density is documented to reduce sensitivity and specificity of mammography. However, little is known regarding the effect of normal background parenchymal enhancement on accuracy of breast MRI. The purpose of this study was to evaluate the effect of background parenchymal enhancement on MRI diagnostic performance. MATERIALS AND METHODS. A review of our established MRI data identified all women undergoing breast MRI from March 1, 2006, through June 30, 2007. Prospectively reported background parenchymal enhancement categories of minimal, mild, moderate, or marked (anticipated BI-RADS MRI lexicon definitions) and assessments were extracted from the database for each patient. Outcomes were determined by pathologic analysis, imaging, and linkage with the regional tumor registry with a minimum of 24 months of follow-up. Patients were dichotomized into categories of minimal or mild versus moderate or marked background parenchymal enhancement. Associations with patient age, abnormal interpretat...
153 citations
Authors
Showing all 735 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Frederick R. Appelbaum | 127 | 677 | 66632 |
| Gary H. Lyman | 108 | 694 | 52469 |
| Elihu H. Estey | 103 | 667 | 43416 |
| Michael Boeckh | 100 | 439 | 35180 |
| Peter S. Nelson | 96 | 425 | 47923 |
| David G. Maloney | 95 | 491 | 37057 |
| Stephanie J. Lee | 92 | 573 | 43888 |
| John A. Hansen | 89 | 411 | 28468 |
| Jerald P. Radich | 88 | 412 | 37725 |
| H. Joachim Deeg | 86 | 458 | 29932 |
| David C. Dale | 85 | 406 | 24613 |
| Barry E. Storer | 85 | 394 | 28713 |
| Oliver W. Press | 80 | 424 | 23103 |
| Brenda M. Sandmaier | 79 | 434 | 28049 |
| Celestia S. Higano | 78 | 423 | 38785 |